![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
X
Active Filter(s):
Details:
The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Lead Product(s): Mirtazapine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Recipient: Kindred Biosciences
Deal Size: Undisclosed Upfront Cash: $43.0 million
Deal Type: Divestment March 16, 2020